BRCA2 and prostate carcinoma: Finally, at the gene-level, we tested for genetic association between aggressive prostate cancer and controls, and found that PTVs in BRCA2 (OR = 8.23 [6.17–10.85], P = 1.47 × 10−36) and ATM (OR = 5.27 [3.65–7.46], P = 1.74 × 10−16) were significantly associated with aggressive disease (Table 2, Supplementary Data 10–13, Supplementary Figs. 9–12).